Abeona Therapeutics Inc. (NasdaqCM: ABEO)
Health Care · Biotechnology · US
$6.06
-0.49% today · -15.8% 1Y
Abeona Therapeutics Inc. (NasdaqCM: ABEO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $348.25M and employs 226 people.
Over the last twelve months the share price has lost 15.8%, trading between 4.00 and 7.65.
Tweenvest scores Abeona Therapeutics Inc. across four factors: quality 27/100, value 70/100. Its strongest factor is value.
ABEO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $348.25M
- Revenue (TTM)
- $25.52M
- P/E
- —
- EPS
- -1.18
- Dividend yield
- —
- Beta (5Y)
- 1.34
- 52-week high
- $7.65
- 52-week low
- $4.00
- Avg volume (3M)
- —
- Shares outstanding
- 57.18M
- Employees
- 226
- Next earnings
- —
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
- ISIN
- US00289Y2063
- Founded
- 1974
- Listed since
- Sep 19, 1980
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €875.40 | +1.30% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.70 | +2.02% |
Figures last refreshed Aug 18, 2026.